Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


10.12.2018

2 BMC Gastroenterol
1 Dtsch Med Wochenschr
1 J Hepatol
3 J Med Virol
3 J Viral Hepat
1 JAMA
1 Lancet Gastroenterol Hepatol
1 Lancet HIV
7 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Gastroenterol

  1. LI JH, Zhu N, Min YB, Shi XZ, et al
    Ultrasonic assessment of liver stiffness and carotid artery elasticity in patients with chronic viral hepatitis.
    BMC Gastroenterol. 2018;18:181.
    PubMed     Text format     Abstract available

  2. GAO F, Li X, Wan G, Li Y, et al
    Development and external validation of a prognostic nomogram for acute decompensation of chronic hepatitis B cirrhosis.
    BMC Gastroenterol. 2018;18:179.
    PubMed     Text format     Abstract available


    Dtsch Med Wochenschr

  3. ZEUZEM S
    [Treatment of Hepatitis C: State of the Art 2018].
    Dtsch Med Wochenschr. 2018;143:1784-1788.
    PubMed     Text format     Abstract available


    J Hepatol

  4. RIVEIRO-BARCIELA M, Munoz-Couselo E, Fernandez-Sojo J, Diaz-Mejia N, et al
    Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?
    J Hepatol. 2018 Nov 28. pii: S0168-8278(18)32504.
    PubMed     Text format    


    J Med Virol

  5. BEN S, Yan WJ, Xia W, Juan FJ, et al
    VDR rs7975232/ApaI genetic variation predicts sustained HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with pegylated interferon.
    J Med Virol. 2018 Dec 5. doi: 10.1002/jmv.25373.
    PubMed     Text format     Abstract available

  6. SINGH L, Bell TG, Yousif M, Kramvis A, et al
    Response of hepatitis B virus to anti-retroviral treatment containing lamivudine in HBsAg-positive and HBsAg-negative HIV-positive South African adults.
    J Med Virol. 2018 Dec 4. doi: 10.1002/jmv.25375.
    PubMed     Text format     Abstract available

  7. COSTA JEF, Morais VMS, Goncales JP, Medeiros AADP, et al
    Occult Hepatitis B Virus Infection in Patients with Leprosy.
    J Med Virol. 2018 Dec 4. doi: 10.1002/jmv.25374.
    PubMed     Text format     Abstract available


    J Viral Hepat

  8. LEE SS, Kim CY, Kim BR, Cha RR, et al
    Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13047.
    PubMed     Text format     Abstract available

  9. RAUWOLF K, Herbruggen H, Zollner S, Thorer H, et al
    Durable control of Hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic hematopoietic stem cell transplantation.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13046.
    PubMed     Text format     Abstract available

  10. POURMARZI D, Hall L, Hepworth J, Smirnov A, et al
    Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of Hepatitis C Virus infection: a mixed method systematic review.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13045.
    PubMed     Text format     Abstract available


    JAMA

  11. GRENNAN D
    Treating Hepatitis C.
    JAMA. 2018;320:2280.
    PubMed     Text format    


    Lancet Gastroenterol Hepatol

  12. THE LANCET GASTROENTEROLOGY HE
    Drug pricing: still a barrier to elimination of HCV.
    Lancet Gastroenterol Hepatol. 2018;3:813.
    PubMed     Text format    


    Lancet HIV

  13. THE LANCET HIV
    Microelimination could be a big deal for HCV and HIV services.
    Lancet HIV. 2018;5:e605.
    PubMed     Text format    


    PLoS One

  14. MADDEN A, Hopwood M, Neale J, Treloar C, et al
    Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
    PLoS One. 2018;13:e0207226.
    PubMed     Text format     Abstract available

  15. JUANBELTZ R, Perez-Garcia A, Aguinaga A, Martinez-Baz I, et al
    Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain.
    PLoS One. 2018;13:e0208554.
    PubMed     Text format     Abstract available

  16. BOUACIDA L, Suin V, Hutse V, Boudewijns M, et al
    Distribution of HCV genotypes in Belgium from 2008 to 2015.
    PLoS One. 2018;13:e0207584.
    PubMed     Text format     Abstract available

  17. ABADIE R, Goldenberg S, Welch-Lazoritz M, Fisher CB, et al
    Establishing trust in HIV/HCV research among people who inject drugs (PWID): Insights from empirical research.
    PLoS One. 2018;13:e0208410.
    PubMed     Text format     Abstract available

  18. RAU M, Schmitt J, Berg T, Kremer AE, et al
    Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients.
    PLoS One. 2018;13:e0208225.
    PubMed     Text format     Abstract available

  19. RAJAMOORTHY Y, Radam A, Taib NM, Rahim KA, et al
    The relationship between perceptions and self-paid hepatitis B vaccination: A structural equation modeling approach.
    PLoS One. 2018;13:e0208402.
    PubMed     Text format     Abstract available

  20. LAWRENCE YA, Dangott LJ, Rodrigues-Hoffmann A, Steiner JM, et al
    Proteomic analysis of liver tissue from dogs with chronic hepatitis.
    PLoS One. 2018;13:e0208394.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: